Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 1347 plus Fulvestrant in FGFR-amplified Breast Cancer
NCT03344536Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2017
- Primary completion
- Aug 2021
- Countries
- 1
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Modality
- Small Molecules
- Drugs
- zoligratinib
- Conditions
- breast cancer
01
Overview
Phase 2, open-label, single-arm trial of zoligratinib in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Dose Limiting Toxicity at 1 year and Best Overall Response at 1 year. Started Nov 2017; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
fulvestrant and Debio 1347
Combination of zoligratinib and fulvestrant
03
Who it enrols
Patients with metastatic HR+/HER2- breast cancer with FGFR amplification.
04
Endpoints
Primary
Dose Limiting Toxicity
Best Overall Response
Beyond the preview
Go deeper on NCT03344536.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03344536.